{
  "docId": "019dd923-622c-750b-8b9a-2a2468219173",
  "docSlug": "ce565b841c40",
  "documentTitle": "Nevro Corp. (NVRO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Kir Kahlon",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-01-07 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 144,
  "pageCount": 239,
  "prevPage": 143,
  "nextPage": 145,
  "slideType": "villain_critique",
  "function": "name_villain",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "Uses quotes from KOLs and former users to frame the company as a 'one-trick pony' facing inevitable decline.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "bullet_list",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-2a2468219173/144",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173#slide-144",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "After spending a decade pushing high frequency stimulation and trashing low-frequency as ineffective and dangerous, experts described the company’s sudden embrace of low-frequency as an admission of defeat and a sign the company is going \"the way of the Dodo.\"",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b342-6776f8e7ea1d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.88,
        "x": 0.06,
        "y": 0.28
      },
      "kind": "list",
      "text": "KOL’s state the industry has moved on from high-frequency and that Omnia is an admission of failure",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "25654287-526e-42fc-a793-9e07f8249f77",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.88,
        "x": 0.06,
        "y": 0.58
      },
      "kind": "list",
      "text": "Omnia indicates that Nevro’s future is “problematic” and that it’s going “the way of the Dodo bird” with price pressure and new entrants",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a87d20fa-df48-41a3-b74d-dc99586d12e8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.88,
        "x": 0.06,
        "y": 0.14
      },
      "kind": "paragraph",
      "text": "Comments by former Nevro executives/reps, competitors, and KOL’s/doctors indicate that Omnia is not only a dud, but that it erodes Nevro’s credibility and muddles their message. After spending a decade pushing high frequency stimulation and trashing low-frequency as ineffective and dangerous, experts described the company’s sudden embrace of low-frequency as an admission of defeat and a sign the company is going “the way of the Dodo.”",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d2f2f6ee-1fd3-4516-a0a1-e841a099bde2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.85,
        "x": 0.09,
        "y": 0.32
      },
      "kind": "quote",
      "text": "“Nevro initially tried to blow everybody out of the water with, \"Look, we have 10khz frequency\" And I know the key engineer over there. When the PROCO study came out, it showed excellent sub-perception outcomes at 1khz. All of a sudden everybody said, \"Who needs 10k?\" And they then said \"Nobody can have 10khz but us,\" and Boston Scientific and the other companies said, \"It's all yours.\" So, Nevro failed with 10k. Now what they have to do is reinvent themselves, so they re-marketed Omnia. Here's a company that said, \"Paresthesia is awful.\" Now they have to give in and offer paresthesia.” - KOL and former high volume Nevro user",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "00c4d9de-d479-4c1f-a83e-851c77ef2532",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.09,
        "y": 0.51
      },
      "kind": "quote",
      "text": "“If paresthesia-free was such a good thing, why come out with supposedly new technology? Maybe it’s marketing.” - KOL",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "46d5c057-a241-4f3f-ad60-cda7218913ae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.09,
        "y": 0.64
      },
      "kind": "quote",
      "text": "“I give them a lot of credit that they've been able to survive financially being a one-trick pony, but the fact that they came out with Omnia does mean the future is problematic, because now they've realized that they're not anything special, they're just another stimulator company—what is going to distinguish them from the other companies.” - High volume implanter and moderate Nevro user",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4bcf3a87-9eed-4fb7-9455-e9c7e19d24a8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.09,
        "y": 0.77
      },
      "kind": "quote",
      "text": "“There are going to be more entrants to the market, and that's going to cause price pressure. Nevro is going to go the way of the Dodo bird eventually. That's why they had to do Omnia.” - KOL and high volume implanter",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f8298202-4349-47f5-81ff-a7db64b9f6ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "\"Nevro initially tried to blow everybody out of the water with, 'Look, we have 10khz frequency' And I know the key engineer over there. When the PROCO study came out, it showed excellent sub-perception outcomes at 1khz. All of a sudden everybody said, 'Who needs 10k?' And then they sued and said 'Nobody can have 10khz but us,' and Boston Scientific and the other companies said, 'It's all yours.' So, Nevro failed with 10k. Now what they have to do is reinvent themselves, so they re-marketed Omnia. Here's a company that said, 'Paresthesia is awful.' Now they have to give in and offer paresthesia.\" — KOL and former high volume Nevro user",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b342-6b22fef58e66",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.06,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "84c07f97-814e-42ff-a69f-fcf6d93bfb3c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.88,
        "x": 0.06,
        "y": 0.09
      },
      "kind": "title",
      "text": "10. The new Omnia stimulator, the centerpiece of Nevro’s turnaround hopes, is a Hail Mary and colossal flop",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "66be8472-c773-4d34-8b42-e2c1d9054525",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.06,
        "y": 0.04
      },
      "kind": "title",
      "text": "Scorpion Capital | Nevro (NYSE: NVRO)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eabbe4dc-0128-4ef0-b9d3-9073a72dd320",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 150,
      "from": 51,
      "beatId": "903c076a-f368-4ca1-844c-277874c1afb2",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Victory",
      "beatSlug": "overcoming-monster-the-victory",
      "evidence": "The deck presents a conclusion that Nevro's problems are insurmountable",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}